BrainsWay Ltd.

NASDAQ•BWAY

CEO: Mr. Hadar Levy

セクター: Healthcare

業種: Medical - Devices

上場日: 2019-04-17

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

連絡先情報

Bynet Building, 3rd Floor 19 Hartum Street Har Hotzvim, Jerusalem, 9777518, Israel

972-2-582-4030

www.brainsway.com

時価総額

$537.75M

PER (TTM)

62.2

26.6

配当利回り

52週高値

$14.65

52週安値

$3.92

52週レンジ

91%

順位61Top 91.5%

2.0

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$14.64M+0.00%

直近4四半期の推移

EPS

$0.16+0.00%

直近4四半期の推移

フリーCF

$518.79K+0.00%

直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Revenue Jumps 29% Total revenues reached $41.0M in 2024, marking a 29% increase driven by higher system sales and leases.

Achieved Net Profitability Company achieved net income of $2.9M in 2024, reversing the $(4.2M) net loss reported in the prior year.

Operating Cash Flow Strong Net cash provided by operating activities was $10.3M for 2024, significantly up from $1.3M in 2023.

Secured $20M Financing Consummated private placement with Valor in November 2024, securing aggregate gross proceeds of approximately $20M.

リスク要因

Future Profitability Uncertain History of operating losses persists; management cannot ensure existing capital suffices for future requirements or sustained profitability.

Geopolitical Supply Chain Risks Geopolitical instability, including regional conflicts, causes supply chain disruptions, increased shipping costs, and operational uncertainty.

Market Acceptance Critical Success depends entirely on market perception and acceptance of Deep TMS technology as a safe and effective treatment option.

Clinical Trials Uncertainty Developing new indications requires lengthy, expensive clinical trials with uncertain outcomes, potentially delaying commercialization.

見通し

Focus on Core Commercialization Strategy centers on scaling full commercialization for MDD, OCD, and smoking addiction, focusing heavily on the large US market.

Advance Next-Gen Technology Actively developing next-generation multichannel device utilizing patented rotational field TMS technology for broader stimulation.

Pursue New Indications Intends to conduct clinical trials for additional psychiatric, neurological, and addiction disorders presenting promising market opportunities.

Increase International Footprint Working to expand commercial footprint across Europe, Asia, Latin America, and the Middle East via distributors and agents.

同業比較

売上高 (TTM)

TCMD

$329.52M

+12.5%

VMD

$270.28M

+20.5%

CERS

$206.13M

+14.3%

粗利益率 (最新四半期)

SGHT

87.3%

+2.5pp

CVRX

86.3%

+3.6pp

DCTH

85.5%

+1.9pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
TCMD	$604.28M	31.6	9.3%	5.8%
BWAY	$537.75M	62.2	12.0%	6.0%
NPCE	$474.37M	-21.5	-105.7%	67.1%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

8.3%

安定成長

4四半期純利益CAGR

38.7%

収益性の大幅な改善

キャッシュフロー安定性

75%

キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年5月11日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし